18 results on '"Fotopoulou, Christina"'
Search Results
2. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival
- Author
-
Avesani, Giacomo, Arshad, Mubarik, Lu, Haonan, Fotopoulou, Christina, Cannone, Federico, Melotti, Roberto, Aboagye, Eric, and Rockall, Andrea
- Published
- 2020
- Full Text
- View/download PDF
3. What is the evidence for lymphadenectomy in presumed early ovarian cancer?
- Author
-
Schmalfeldt, Barbara, Brambs, Christine, Burges, Alexander, El-Balat, Ahmed, Emons, Günter, Fink, Daniel, Fotopoulou, Christina, Gropp-Meier, Martina, Hanker, Lars-Christian, Harter, Philipp, Hasenburg, Annette, Hauptmann, Steffen, Hilpert, Felix, Kimmig, Rainer, Kommoss, Stefan, Kurzeder, Christian, Mahner, Sven, Marmé, Frederik, Mayr, Doris, Meier, Werner, Meinhold-Heerlein, Ivo, Mustea, Alexander, Ortmann, Olaf, Oskay-Özcelik, Gülten, Pfisterer, Jacobus, Pölcher, Martin, Runnebaum, Ingo B., Schröder, Willibald, Tanner, Berno, Wagner, Uwe, Wimberger, Pauline, and Sehouli, Jalid
- Published
- 2019
- Full Text
- View/download PDF
4. Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study.
- Author
-
Cummins, Carole, Kumar, Satyam, Long, Joanna, Balega, Janos, Broadhead, Tim, Duncan, Timothy, Edmondson, Richard J., Fotopoulou, Christina, Glasspool, Rosalind M., Kolomainen, Desiree, Leeson, Simon, Manchanda, Ranjit, Morrison, Jo, Naik, Raj, Tidy, John A., Wood, Nick, and Sundar, Sudha
- Subjects
RESEARCH ,REPORTING of diseases ,OVARIAN tumors ,SPECIALTY hospitals ,CONFIDENCE intervals ,CANCER treatment ,SURVIVAL analysis (Biometry) ,CYTOREDUCTIVE surgery ,DEMOGRAPHIC characteristics ,GYNECOLOGIC care ,LOGISTIC regression analysis ,PROPORTIONAL hazards models - Published
- 2022
- Full Text
- View/download PDF
5. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
- Author
-
Bowtell, David D., Böhm, Steffen, Ahmed, Ahmed A., Aspuria, Paul-Joseph, Bast, Robert C., Beral, Valerie, Berek, Jonathan S., Birrer, Michael J., Blagden, Sarah, Bookman, Michael A., Brenton, James D., Chiappinelli, Katherine B., Martins, Filipe Correia, Coukos, George, Drapkin, Ronny, Edmondson, Richard, Fotopoulou, Christina, Gabra, Hani, Galon, Jérôme, and Gourley, Charlie
- Subjects
OVARIAN cancer patients ,CANCER-related mortality ,HEALTH outcome assessment ,CANCER research ,MISSENSE mutation ,CELL cycle ,TUMOR prevention ,OVARIAN tumors ,PROGNOSIS ,SURVIVAL ,TUMORS ,TUMOR grading ,PREVENTION - Abstract
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients.
- Author
-
Sehouli, Jalid, Fotopoulou, Christina, Erol, Edibe, Richter, Rolf, Reuss, Alexander, Mahner, Sven, Lauraine, Eric Pujade, Kristensen, Gunnar, Herrstedt, Jörn, du Bois, Andreas, and Pfisterer, Jacobus
- Subjects
- *
BALDNESS , *BIOMARKERS , *CANCER chemotherapy , *CONFIDENCE intervals , *EVALUATION of medical care , *META-analysis , *DATA analysis , *OVARIAN tumors , *RANDOMIZED controlled trials , *DIAGNOSIS , *TUMOR treatment - Abstract
Purpose Alopecia is a common side-effect of chemotherapy and affects quality of life of cancer patients. Some patients and physicians believe that alopecia could be a surrogate marker for response to chemotherapy and impact on prognosis. However, this was never been tested in a sufficiently large cohort of ovarian cancer patients. Patients and methods We analysed retrospectively the meta-databank of four prospective randomised phase-III-trials with platinum- and taxane-based 1st-line-chemotherapy in patients with advanced epithelial ovarian cancer (EOC) regarding the impact of alopecia overall outcome. Results For 4705 (92.0%) of a total of 5114 EOC-patients alopecia was documented. They had received on median six cycle platinum-taxane chemotherapy (range 0–11) with 4186 (89.0%) having completed ⩾6 cycles. Worst alopecia grade was 0 in 2.4%, 1 in 2.9% and 2 in 94.7% of the patients. In a univariate analysis, including all patients, grade-0/1 alopecia was associated with significantly lower progression free survival (PFS) and overall survival (OS) compared to grade-2 alopecia. However when assessing only those patients who completed ⩾6 chemotherapy-cycles and hence eliminating the bias of lower total dose of treatment, alopecia failed to retain any significant impact on survival in the multivariate analysis. Merely the time point of alopecia onset was an independent prognostic factor of survival: patients who developed grade-2 alopecia up to cycle 3 had a significantly longer OS compared to patients who experienced alopecia later during therapy (hazard ratio (HR): 1.25; 95% confidence interval (CI): 1.04–1.50). Conclusions Within a large EOC-patient cohort with 1st-line platinum- and taxane-based chemotherapy early onset alopecia appears to be significantly associated with a more favourable outcome in those patients who completed ⩾6 chemotherapy cycles. It remains to be elucidated if early onset alopecia is just a surrogate marker for higher sensitivity to chemotherapy or if other biological effects are underlying. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
- Author
-
Woopen, Hannah, Pietzner, Klaus, Richter, Rolf, Fotopoulou, Christina, Joens, Thomas, Braicu, Elena Ioana, Mellstedt, Håkan, Mahner, Sven, Lindhofer, Horst, Darb-Esfahani, Silvia, Denkert, Carsten, and Sehouli, Jalid
- Subjects
EPITHELIAL cell culture ,CANCER chemotherapy ,OVARIAN cancer treatment ,IMMUNOHISTOCHEMISTRY ,PROGNOSIS - Abstract
Objective: Epithelial cell adhesion molecule (EpCAM) has experienced a renaissance lately as a binding site for targeted therapy as well as a prognostic marker in epithelial malignancies. Aim of this study was to study EpCAM as a potential prognostic marker in epithelial ovarian cancer (EOC). Methods: EpCAM expression was assessed by immunohistochemistry on paraffin-embedded primary EOC-tissue samples. EpCAM overexpression was defined as an expression of EpCAM of 76% to 100%. Tissue samples and clinical data were systematically collected within the international and multicenter "Tumorbank Ovarian Cancer" network. Results: Seventy-four patients, diagnosed with EOC between 1994 and 2009, were included in the study (median age, 56 years; range, 31 to 86 years). The majority of the patients (81.1%) presented with an advanced stage International Federation of Gynecology and Obstetrics (FIGO) III/IV disease. Histology was of the serous type in 41 patients (55.4%), endometrioid in 19 (25.6%), and mucinous in 14 (19%). EpCAM was overexpressed in 87.7%. Serous tumors overexpressed EpCAM significantly more often than mucinous tumors (87.8% vs. 78.6%, p=0.045); while no significant difference was noted between the other histological subgroups. EpCAM overexpression was significantly associated with a better progression free survival and higher response rates to platinum based chemotherapy (p=0.040 and p=0.048, respectively). EpCAM was identified as an independent prognostic marker for overall survival (p=0.022). Conclusion: Our data indicate a significant association of EpCAM overexpression with a more favorable survival in EOC-patients. Serous cancers showed a significant EpCAM overexpression compared to mucinous types. Larger multicenter analyses are warranted to confirm these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Salvage Surgery Due To Bowel Obstruction in Advanced or Relapsed Ovarian Cancer Resulting in Short Bowel Syndrome and Long-Life Total Parenteral Nutrition.
- Author
-
Fotopoulou, Christina, Braicu, Elena Ioana, Kwee, Sara-Lea, Kuhberg, Marc, Richter, Rolf, Pietzner, Klaus, Feldheiser, Aarne, Bahra, Marcus, Schmidt, Sven Christian, and Sehouli, Jalid
- Abstract
Salvage surgery for patients with highly advanced or relapsed epithelial ovarian cancer (EOC) complicated by bowel obstruction and resulting in short bowel syndrome (SBS) constitutes a therapeutic dilemma. Our aim was to evaluate surgical and clinical outcome in these highly palliative situations.We evaluated all patients with EOC who underwent salvage extraperitoneal en bloc intestinal resection with terminal ileostomy or jejunostomy resulting in SBS and total parenteral nutrition owing to bowel obstruction between May 2003 and January 2012 in our institution.Thirty-seven patients were identified (median age, 58 years; range, 22-71 years), 3 (8.1%) with primary and 34 (91.6%) with relapsed EOC. Five patients (13.5%) were platinum sensitive. Median residual intestinal length was 70 cm (range, 10-180 cm); 21 patients (56.8%) had a residual intestinal length less than 1 m. Operative 30-day mortality and major morbidity rates were 10% and 51%, respectively. Median overall survival was 5.6 months (range, 0.1-49 months). One-year and 2-year overall survival rates were 18.3% (95% confidence interval, 5.1%-31.5%) and 8.1% (95% confidence interval, 0%-18.0)%, respectively. Within a median follow-up period of 5 months (range, 0.2-49 months), 4 patients (10.8%) are still alive. No significant differences in survival were seen between patients with or without major complications, tumor residuals, or residual intestinal length of less than 1 m versus greater than 1 m.Salvage palliative surgery in EOC due to bowel obstruction resulting in SBS and in need of long-life total parenteral nutrition is associated with high morbidity rates and low overall survival. These surgeries should ideally be performed only in a multidisciplinary setting with adequate infrastructure and possibility of home care support. Conservative management should be the route of action in the absence of acute abdomen or intestinal perforation. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer.
- Author
-
Pietzner, Klaus, Woopen, Hannah, Richter, Rolf, Joens, Thomas, Braicu, Elena Ioana, Dimitrova, Desislava, Mellstedt, Håkan, Darb-Esfahani, Silvia, Denkert, Carsten, Lindhofer, Horst, Fotopoulou, Christina, and Sehouli, Jalid
- Abstract
Ovarian cancer (OC) recurrence constitutes a therapeutic dilemma with various novel targeted agents emerging that offer alternative treatment options. The aim of the present study was to evaluate and compare epithelial cell adhesion molecule (EpCAM) expression profiles in paired tumor samples of patients with OC relapse.EpCAM expression was analyzed by immunohistochemistry using the avidin-biotin-complex method on paraffin-embedded OC tissues obtained at primary surgery as well as on corresponding tumor samples of the same patients at relapse. The EpCAM overexpression was defined as 76% to 100% of tumor cells positively stained for EpCAM. Clinical data were collected within the Tumorbank Ovarian Cancer Network.Nineteen patients with serous OC histology were included in the study (median age at primary diagnosis, 50 years; range, 40-74 years). The majority of the patients (95%) presented with International Federation of Gynecology and Obstetrics stage III/IV, and 68.4% of the tumors were poorly differentiated. A complete macroscopic tumor resection could be achieved in 15 patients (78.9%) at diagnosis. Epithelial cell adhesion molecule overexpression was detected in 17 (89%) of the primary and 16 (84%) of the recurrent tumors (P = 1.0); hence, no significant change of the EpCAM expression profile could be identified over time.Epithelial cell adhesion molecule expression profile appears to remain stable during the course from the primary throughout the relapse of serous OC. The results indicate that EpCAM might be an interesting therapeutic target structure in serous OC. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. What are the individual perceptions of patients with borderline tumours of the ovary in regard to pathogenesis and prognosis? A structured survey on 60 women.
- Author
-
Fotopoulou, Christina, Bugariu, Marios, Braicu, Elena Ioana, Lichtenegger, Werner, and Sehouli, Jalid
- Subjects
- *
OVARIAN tumors , *CANCER in women , *ONCOLOGY , *CARCINOGENESIS , *CANCER-related mortality , *CANCER risk factors - Abstract
Limited data exist about the perception of patients with borderline ovarian tumours (BOT). We assessed the individual perception of patients with BOT, with special focus on the biological-behaviour of the disease. Sixty patients with BOT who underwent surgery during January 2001 to June 2009 were interviewed by a 9-item-questionnaire, at the earliest, 12months postoperatively. The aim was to assess their estimation regarding the malignant potential of BOT, its impact on their future fertility, the risk of recurrence and death and the possible causes of BOT. Seventeen women incriminated occupational-stress as a causative factor; 8 women genetic-predisposition, and 7 women personal-stress. Only 10 (16.7%) patients evaluated the BOT malignant potential as equivalent to that of a benign ovarian-cyst, while 28 (46.7%) and 20 (33.3%) patients believed carrying the same or equivalent recurrence- and mortality-risk, respectively, like patients with ovarian cancer (OC). Most fertile patients (19/23; 82.6%) felt adequately informed about the impact of BOT on their future fertility, while four patients stated being insufficiently informed. Despite the overall favourable BOT prognosis, affected patients appear to correlate their malignant potential close to that of OC with an equivalent high risk of recurrence. However, patients do not expect to die of BOT. There is a high need to intensify information process regarding BOT. Future trials are warranted to evaluate whether this may substantially influence the patients' perspectives. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
11. Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: Lymph-node mapping and identification of predictive factors for lymph-node status
- Author
-
Fotopoulou, Christina, Savvatis, Konstantinos, Kraetschell, Robert, Schefold, Joerg C., Lichtenegger, Werner, and Sehouli, Jalid
- Subjects
- *
LYMPH nodes , *ENDOMETRIAL cancer , *MESENTERIC artery , *SURGICAL therapeutics , *METASTASIS , *MEDICAL statistics , *SURGICAL excision - Abstract
Abstract: Objective: To systematically assess the metastatic pattern of intermediate- and high-risk endometrial cancer in pelvic and para-aortic lymph-nodes and to evaluate risk factors for lymph-node metastases. Study Design: Between 01/2005 and 01/2009 62 consecutive patients with intermediate- and high-risk endometrial cancer who underwent a systematic surgical staging including pelvic and para-aortic lymphadenectomy were enrolled into this study. Patients’ characteristics, histological findings, lymph-node localization and involvement, surgical morbidity and relapse data were analyzed. Univariate analysis was performed to define risk factors for lymph-node metastasis. Results: Of the 13 patients (21%) with positive lymph-nodes (N1), 8 (61.5%) had both pelvic and para-aortic lymph-nodes affected, 2 (15.4%) only para-aortic and 3 (23%) only pelvic lymph-node metastases. Overall, 54% of the N1-patients had positive lymph-nodes above the inferior mesenteric artery (IMA) to the level of the renal veins. Univariate analysis revealed lymph vascular space invasion (p-value: <0.001), vascular-space-invasion (p-value: <0.001) and incomplete tumor resection (p-value: 0.008) as significant risk factors for N1-status. Overall and progression-free survival was not significantly different between N1- and N0-patients. Conclusions: Since the proportion of N1-endometrial cancer patients with positive para-aortic lymph-nodes is, at 76%, considerably high, and more than half of them have affected lymph-nodes above the IMA-level, lymphadenectomy for endometrial cancer should be extended up to the renal veins, when indicated. The therapeutic impact of systematic lymphadenectomy on overall and progression-free survival has still to be evaluated in future prospective randomized studies. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
12. Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
- Author
-
Kim, Ji Hyun, Han, Kyung Hee, Park, Eun Young, Kim, Eun Taeg, Kim, Eun Jeong, Tan, David S.P., Lee, Jung-Yun, Park, Sang-Yoon, Fotopoulou, Christina, and Lim, Myong Cheol
- Subjects
- *
IMMUNE checkpoint inhibitors , *CANCER chemotherapy , *TREATMENT effectiveness , *ENDOMETRIAL cancer , *RACE - Abstract
The combination of immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy has emerged as a highly promising primary option for advanced or recurrent endometrial cancer (EC). The study aimed to evaluate treatment efficacy of ICIs with cytotoxic chemotherapy in EC. We conducted a comprehensive review of randomized controlled trials up to November 11, 2023, focusing on immunotherapy combined with chemotherapy versus chemotherapy alone for EC. The primary endpoint was the pooled hazard ratio (HR), which was further analyzed across subgroups based on mismatch repair (MMR) status, race, histology, and programmed death-ligand 1 (PD-L1) status. The protocol was registered in PROSPERO (CRD42023475669). Four trials with 2335 patients were analyzed. ICIs with chemotherapy significantly prolonged progression-free survival (PFS) (HR, 0.70; 95% CI, 0.62–0.79) and overall survival (OS) (HR, 0.75; 95% CI, 0.63–0.89) compared to chemotherapy alone. Stratification by MMR status showed substantial benefits for dMMR (PFS; HR, 0.33; 95% CI, 0.26–0.43; OS; HR, 0.37; 95% CI, 0.22–0.91) over pMMR cohorts in both PFS and OS. In the subgroup analysis, there was significant PFS advantage in Caucasian (HR, 0.63; 95% CI, 0.54–0.72) over non-Caucasian, in endometrioid histology (HR, 0.66; 95% CI, 0.56–0.78) over non-endometrioid, and in PD-L1 positive (HR, 0.39; 95% CI, 0.19–0.81) over PD-L1 negative population. ICIs combined with platinum-based chemotherapy significantly prolonged PFS and OS in patients with advanced or recurrent EC. Patients with dMMR status, Caucasians, endometrioid histology, and positive PD-L1 status showed significant PFS benefits, emphasizing the need for personalized treatment approaches to improve outcomes. • ICIs and platinum-based chemotherapy are primary options for advanced or recurrent EC, and prolong PFS and OS. • A substantial PFS benefit was observed in patients with Caucasian race, endometrioid histology, and PD-L1 positivity. • Personalized treatments are vital in ICI therapy, considering factors like MMR status, ethnicity, and PD-L1 expression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites.
- Author
-
Fotopoulou, Christina, Berg, Thomas, Hausen, Annekristin, Hennig, René, Jalan, Rajiv, Malagó, Massimo, Capel, Jeroen, De Gottardi, Andrea, and Stirnimann, Guido
- Subjects
- *
CYSTOTOMY , *INFECTION risk factors , *ASCITES , *CANCER patients , *LENGTH of stay in hospitals , *MEDICAL cooperation , *MEDICAL protocols , *PALLIATIVE treatment , *PARACENTESIS , *PERITONITIS , *QUALITY of life , *KIDNEY failure , *RESEARCH , *SURVIVAL , *PERITONEUM tumors , *TREATMENT effectiveness , *RETROSPECTIVE studies , *TREATMENT duration , *MEDICAL drainage , *SURGICAL wound dehiscence , *DISEASE risk factors ,SURGICAL complication risk factors - Abstract
Background: Malignant Ascites (MA) is a therapeutic dilemma significantly impairing patients' quality of life (QoL). The Sequana Medical alfapump System (AP), a subcutaneous, externally rechargeable, implantable device, continually draining ascites via the urinary bladder, has been well established in liver cirrhosis, but not yet in MA. The AP-system was evaluated in cancer patients in reducing the need for large volume paracentesis (LVP). Methods: A retrospective multicentre evaluation of all eligible patients who received an AP for MA-palliation was performed. AP was evaluated for its ability to reduce LVP and cross-correlated with adverse events (AE), survival and retrospective physician-reported QoL. Results: Seventeen patients with median age of 63 years (range: 18–81), 70.6% female, across 7 primary tumour types were analysed. Median duration of AP-implantation was 60 min (range: 30–270) and median post-implantation hospital stay: 4 days (range: 2–24). Twelve protocol-defined AE occurred in 5 patients (29.4%): 4 kidney failures, 4 pump/catheter-related blockages, 3 infections/peritonitis and 1 wound dehiscence. Median ascitic volume (AV) pumped daily was 303.6 ml/day (range:5.6–989.3) and median total AV drained was 28 L (range: 1–638.6). Median patient post-AP-survival was 111 days (range:10–715) and median pump survival was 89 days (range: 0–715). Median number of paracenteses was 4 (range: 1–15) per patient pre-implant versus 1 (range: 0–1) post-implant (p = 0.005). 71% of patients were reported to have an improvement of at least one physician reported QoL-parameters. Conclusions: AP appears to be effective in palliating patients with MA by an acceptable morbidity profile. Its broader implementation in oncology services should be further explored. Trial registration: NCT03200106; June 27, 2017. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
- Author
-
Kim, Ji Hyun, Kim, Se Ik, Park, Eun Young, Ha, Hyeong In, Kim, Jae-Weon, Coleman, Robert L., Bristow, Robert E., Park, Sang-Yoon, Fotopoulou, Christina, and Lim, Myong Cheol
- Subjects
- *
OVARIAN epithelial cancer , *OVERALL survival , *OVARIAN cancer , *REGRESSION analysis , *CLINICAL trials , *RANDOMIZED controlled trials - Abstract
Current treatment strategies for primary epithelial ovarian cancer (EOC) have significantly evolved, and the value of complete cytoreduction has not yet been reassessed. The study aimed to investigate the impact of residual disease after cytoreductive surgery for EOC on survival outcomes within the recent paradigm of frontline ovarian cancer treatment. We searched relevant literature from the MEDLINE, Embase, and Cochrane Library databases to identify randomized controlled trials and prospective clinical trials of primary EOC published between 1 January 2000 and 22 September 2022. To evaluate the impact of postoperative residual tumors on progression-free survival (PFS) and OS, we constructed a linear regression model for log-transformed median PFS and OS. Patients who did or did not receive first-line maintenance therapy were examined. A total of 97 trials with 43,260 patients were included:2476 received poly(ADP-ribose) polymerase (PARP) inhibitors and 6587 received bevacizumab. Multivariable analysis of the linear regression model of all studies revealed that the median OS increased by 12.97% for every 10% increase in complete cytoreduction rates, independent of the use of systemic maintenance. In the subgroup analysis of patients receiving maintenance therapies, the effect of complete tumor clearance was potentiated, with a median OS increase of 19.13% for every 10% increase in complete cytoreduction rates. Total macroscopic tumor clearance at the initial presentation of EOC significantly prolongs OS. Our results establish the importance of complete surgical cytoreduction, even after the introduction of recent advances in frontline treatment for EOC. • Treatment strategies for primary EOC have evolved, but complete cytoreduction's value remains unassessed. • 97 trials, 43,260 patients, studied residual disease impact on EOC survival after surgery in this meta-analysis. • 10% rise in complete cytoreduction rate linked to a 12.97% increase in median log overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
- Author
-
Kim, Se Ik, Kim, Ji Hyun, Lee, Sanghee, Cho, Hyunsoon, van Driel, Willemien J., Sonke, Gabe S., Bristow, Robert E., Park, Sang-Yoon, Fotopoulou, Christina, and Lim, Myong Cheol
- Subjects
- *
HYPERTHERMIC intraperitoneal chemotherapy , *OVARIAN epithelial cancer , *CANCER chemotherapy , *CYTOREDUCTIVE surgery , *PROGRESSION-free survival - Abstract
The value of hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of cytoreductive surgery (CRS) for epithelial ovarian cancer (EOC) is controversial and its use remains experimental in most national and international guidelines. We wished to systematically evaluate all available evidence. A comprehensive review of data from MEDLINE, EMBASE, and Cochrane Library databases was conducted from the first report on HIPEC in EOC till April 3, 2022. Progression-free survival (PFS) and overall survival (OS) were compared between the HIPEC and control groups. This meta-analysis was registered with PROSPERO (CRD42021265810). Fifteen studies (10 case-control studies and 5 randomized controlled trials [RCTs]) were included in the present meta-analysis. Based on the time interval between the last systemic chemotherapy exposure and timing of CRS +/− HIPEC, all studies and patients' cohorts we classified into recent (<6 months; n = 9 studies/patients cohorts) and non-recent (≥6 months, n = 8 studies/patients cohorts) chemotherapy exposure groups. In the recent chemotherapy exposure group, HIPEC was associated with improvement of both PFS (HR, 0.585; 95% CI, 0.422–0.811) and OS (HR, 0.519; 95% CI, 0.346–0.777). On the contrary, in the non-recent chemotherapy exposure group, HIPEC failed to significantly affect PFS (HR, 1.037; 95% CI, 0.684–1.571) or OS (HR, 0.932; 95% CI, 0.607–1.430). Consistent results were observed in subsequent sensitivity analyses. Our present meta-analysis demonstrates that the value of HIPEC at CRS for EOC appears to depend on the timing of the last systemic chemotherapy exposure. Future trials are awaited to define the role of HIPEC in EOC. • The value of HIPEC at cytoreductive surgery for ovarian cancer remains controversial in most guidelines. • A total of 15 studies of 1861 patients contributed data for meta-analysis. • In the study, the value of HIPEC appears to depend on the timing of the last systemic chemotherapy exposure. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Clinicopathological characteristics and survival outcomes of patients with large cell neuroendocrine carcinoma of the uterine cervix: A systematic review and meta-analysis.
- Author
-
Prodromidou, Anastasia, Phelps, David L., Pergialiotis, Vasilios, Cunnea, Paula, Thomakos, Nikolaos, Rodolakis, Alexandros, Fotopoulou, Christina, and Haidopoulos, Dimitrios
- Subjects
- *
NEUROENDOCRINE tumors , *SURVIVAL rate , *CERVIX uteri , *OVERALL survival , *NEUROENDOCRINE cells , *RENAL cell carcinoma , *CANCER treatment , *META-analysis , *SYSTEMATIC reviews , *PROGNOSIS , *CANCER , *TUMOR classification ,CERVIX uteri tumors - Abstract
Purpose: Large cell neuroendocrine carcinoma (LCNEC) of the cervix represents a rare tumour entity associated with poor prognosis. Knowledge about carcinogenesis and therapeutic options is scarce, while novel therapeutic targeted approaches are limited.Methods: We performed a systematic review of four electronic databases from inception to June 2020. Eligible studies included all reports that addressed survival outcomes of women with LCNEC.Results: A total of 31 case studies including 87 LCNEC patients were identified. Median patients' age was 41 years (range: 21-81). Most women (76.3%) had FIGO stage I-II disease. Overall, 72.0% had surgery, 70.1% received chemotherapy and 50.7% received radiotherapy. Of 13 patients with known HPV-status, 15% were HPV negative. Median overall survival (OS) was 24 months (range: 0.5-151), with 3- and 5-year OS of 42% and 29%, respectively. In multivariate analyses, only surgery and lymphadenectomy significantly associated with survival (Surgery OS: HR 0.14; 95% C.I:0.03-0.71, p = 0.018 / Surgery PFS: HR 0.23, 95% C.I. 0.06, 0.92, p = 0.037 / Lymphadenectomy OS: HR 0.26, 95% C.I. 0.07-0.98, p = 0.046 / Lymphadenectomy PFS: HR 0.30, 95% C.I. 0.09-0.98, p = 0.046). Age, chemotherapy or radiotherapy did not significantly impact survival, but lower stage was associated with improved survival.Conclusion: Cervical LCNECs overall have a poor prognosis, despite their relatively early-stage initial presentation. Surgery and lymphadenectomy appear to significantly affect survival in contrast to chemotherapy and radiotherapy, which appear to have no significant effect on prognosis. Prospective multicentre cancer registries are warranted to improve treatment options for this rare disease. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
17. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
- Author
-
Matsuo, Koji, Hasegawa, Kosei, Yoshino, Kiyoshi, Murakami, Ryusuke, Hisamatsu, Takeshi, Stone, Rebecca L., Previs, Rebecca A., Hansen, Jean M., Ikeda, Yuji, Miyara, Akiko, Hiramatsu, Kosuke, Enomoto, Takayuki, Fujiwara, Keiichi, Matsumura, Noriomi, Konishi, Ikuo, Roman, Lynda D., Gabra, Hani, Fotopoulou, Christina, and Sood, Anil K.
- Subjects
- *
THROMBOEMBOLISM risk factors , *THROMBOEMBOLISM , *CANCER patients , *INTERLEUKINS , *EVALUATION of medical care , *OVARIAN tumors , *SURVIVAL , *TUMOR classification , *CASE-control method , *VEINS , *DISEASE duration , *DISEASE progression , *DATA analysis software , *DIAGNOSIS - Abstract
Background We compared survival outcomes and risk of venous thromboembolism (VTE) among patients with advanced and early-stage ovarian clear cell carcinoma (OCCC) and serous ovarian carcinoma (SOC), as well as potential links with interleukin-6 (IL-6) levels. Methods A multicenter case-control study was conducted in 370 patients with OCCC and 938 with SOC. In a subset of 200 cases, pretreatment plasma IL-6 levels were examined. Findings Patients with advanced OCCC had the highest 2-year cumulative VTE rates (advanced OCCC 43.1%, advanced SOC 16.2%, early-stage OCCC 11.9% and early-stage SOC 6.4%, P < 0.0001) and the highest median levels of IL-6 (advanced OCCC 17.8 pg/mL, advanced SOC 9.0 pg/mL, early-stage OCCC 4.2 pg/mL and early-stage SOC 5.0 pg/mL, P = 0.006). Advanced OCCC (hazard ratio [HR] 3.38, P < 0.0001), thrombocytosis (HR 1.42, P = 0.032) and elevated IL-6 (HR 8.90, P = 0.046) were independent predictors of VTE. In multivariate analysis, patients with advanced OCCC had significantly poorer 5-year progression-free and overall survival rates than those with advanced SOC ( P < 0.01), and thrombocytosis was an independent predictor of decreased survival outcomes ( P < 0.01). Elevated IL-6 levels led to poorer 2-year progression-free survival rates in patients with OCCC (50% versus 87.5%, HR 4.89, P = 0.016) than in those with SOC (24.9% versus 40.8%, HR 1.40, P = 0.07). Interpretation Advanced OCCC is associated with an increased incidence of VTE and decreased survival outcomes, which has major implications for clinical management of OCCC. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
- Author
-
du Bois, Andreas, Ewald-Riegler, Nina, de Gregorio, Nikolaus, Reuss, Alexander, Mahner, Sven, Fotopoulou, Christina, Kommoss, Friedrich, Schmalfeldt, Barbara, Hilpert, Felix, Fehm, Tanja, Burges, Alexander, Meier, Werner, Hillemanns, Peter, Hanker, Lars, Hasenburg, Annette, Strauss, Hans-Georg, Hellriegel, Martin, Wimberger, Pauline, Keyver-Paik, Mignon-Denise, and Baumann, Klaus
- Subjects
- *
LONGITUDINAL method , *MULTIVARIATE analysis , *OVARIAN tumors , *SURVIVAL , *TUMOR classification , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *PROGNOSIS - Abstract
Abstract: Background: Borderline ovarian tumours (BOTs) are recognised as a unique entity of ovarian tumours that do not exert infiltrative destructive growth or stromal invasion. Prognosis of BOT is much better compared to the more common invasive epithelial ovarian cancer. Information regarding prognostic factors is inconclusive and no prospective studies exist that evaluate therapeutic strategies. We therefore started a retrospective–prospective cohort study to better understand BOT and identify scenarios in which future studies could be developed. Methods: Consecutive patients with BOT treated between 1998 and 2008 in 24 German centres were analysed. The retrospective part of the study retrieved patients’ data from hospital records and clinical tumour registries while active follow-up and an independent central pathology review were carried out prospectively. Findings: BOT was confirmed in 950 patients, two thirds had serous BOT and 30.5% mucinous BOT. Most were diagnosed in stage I (82.3%); 7.6% and 10.1% had stages II and III, respectively. Overall, 74 patients (7.8%) experienced relapse and 43 (4.5%) died within the observation period. Multivariate analysis revealed higher stage, incomplete staging, tumour residuals, and organ preservation as independent prognostic factors for disease recurrence. Neither microinvasion nor micropapillary growth pattern showed any significant impact. Of 74 relapsed patients, 30% had malignant transformation to invasive ovarian cancer with five-year progression-free survival and overall survival of 12% and 50%, respectively. Interpretation: Prognosis of BOT correlates with tumour-related as well as surgery-related factors. The balance between recurrence risk and organ preservation and fertility-sparing surgery is an important issue deserving further research. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.